Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 2
2022 2
2025 1
2026 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Risks of Testosterone for Postmenopausal Women.
Pinkerton JV, Blackman I, Conner EA, Kaunitz AM. Pinkerton JV, et al. Endocrinol Metab Clin North Am. 2021 Mar;50(1):139-150. doi: 10.1016/j.ecl.2020.10.007. Epub 2021 Jan 11. Endocrinol Metab Clin North Am. 2021. PMID: 33518182 Review.
Transdermal testosterone therapy, dosed within premenopausal physiologic testosterone ranges, used alone or with menopausal hormone therapy for postmenopausal hypoactive sexual desire disorder, has shown short-term efficacy, with few androgenic side effects. ...Inje …
Transdermal testosterone therapy, dosed within premenopausal physiologic testosterone ranges, used alone or with menopausal hormon …
A Personal Prospective on Testosterone Therapy in Women-What We Know in 2022.
Donovitz GS. Donovitz GS. J Pers Med. 2022 Jul 22;12(8):1194. doi: 10.3390/jpm12081194. J Pers Med. 2022. PMID: 35893288 Free PMC article.
Hormone replacement therapy continues to be a controversial topic in medicine, with certain narratives regarding safety concerns that are not scientifically established in peer-reviewed literature. ...A recent publication on the complications of subcutaneous hormone …
Hormone replacement therapy continues to be a controversial topic in medicine, with certain narratives regarding safety concerns that …
Androgen therapy in midlife and older women: a position statement of the Latin American Association of Gynecological Endocrinology (ALEG).
Pilnik S, Belardo A, Marchesan LB, Camero-Lascano A, Acuña-San Martín M, Elizalde-Cremonte A, Ojeda E, Manzur A, Chedraui P. Pilnik S, et al. Climacteric. 2025 Oct;28(5):529-536. doi: 10.1080/13697137.2025.2548805. Epub 2025 Sep 8. Climacteric. 2025. PMID: 40919649
Transdermal formulations are preferred. Subcutaneous pellets and compounded "bioidentical" Testosterone are not recommended due to risks of supraphysiological dosing and insufficient evidence (Grade C: Low). ...Vaginal DHEA is approved only for genitourinary syndrom …
Transdermal formulations are preferred. Subcutaneous pellets and compounded "bioidentical" Testosterone are not recommended du …
Testosterone Therapy in Women: A Literature Review of Clinical Indications, Dosing, Routes of Administration, and Safety.
Montero Bernaldez J, Burgess ER, Martinez R, Peñalver M. Montero Bernaldez J, et al. Cureus. 2026 Apr 9;18(4):e106713. doi: 10.7759/cureus.106713. eCollection 2026 Apr. Cureus. 2026. PMID: 42110023 Free PMC article. Review.
Despite nearly a century of global use and consistent patient demand, the Food and Drug Administration (FDA) has yet to approve a T formulation for women. This narrative review examines the physiological role of T in females, the clinical presentation of androgen insuffici …
Despite nearly a century of global use and consistent patient demand, the Food and Drug Administration (FDA) has yet to approve a T f …
Safety assessment of compounded non-FDA-approved hormonal therapy versus FDA-approved hormonal therapy in treating postmenopausal women.
Jiang X, Bossert A, Parthasarathy KN, Leaman K, Minassian SS, Schnatz PF, Woodland MB. Jiang X, et al. Menopause. 2021 May 10;28(8):867-874. doi: 10.1097/GME.0000000000001782. Menopause. 2021. PMID: 33973545
OBJECTIVE: To assess the safety and serum estradiol (E2) and total testosterone (T) concentrations in postmenopausal women treated with Pellet Hormonal Therapy (PHT) and Food and Drug Administration approved Hormonal Therapy (FHT). ...Data extracted fr …
OBJECTIVE: To assess the safety and serum estradiol (E2) and total testosterone (T) concentrations in postmenopausal women treated with P …
Concerns About Compounded Bioidentical Menopausal Hormone Therapy.
Pinkerton JV. Pinkerton JV. Cancer J. 2022 May-Jun 01;28(3):241-245. doi: 10.1097/PPO.0000000000000597. Cancer J. 2022. PMID: 35594471
New guidelines recommend government-approved hormone therapy for symptomatic healthy menopausal women younger than 60 years or within 10 years of menopause at the time of initiation. For women requesting bioidentical hormones, those similar to the h …
New guidelines recommend government-approved hormone therapy for symptomatic healthy menopausal women younger than 60 years or …